| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J Palace | |
| C McGuigan | |||
| R Kapoor | |||
| G Mazibrada | |||
| C A Young | |||
| P Molyneux | |||
| R Nicholas | |||
| D Rog | |||
| J Guadagno | |||
| M Craner | |||
| O R Pearson | |||
| P2860 | cites work | Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring | Q22242013 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | Q28278620 | ||
| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial | Q30053056 | ||
| Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
| PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
| The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy | Q30689194 | ||
| JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene | Q34112987 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy | Q34324861 | ||
| Outcome and survival of asymptomatic PML in natalizumab-treated MS patients | Q34562841 | ||
| Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 | ||
| Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
| Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature | Q35314514 | ||
| Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. | Q35609239 | ||
| Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS | Q35938575 | ||
| Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 | ||
| JC virus antibody status underestimates infection rates | Q37079703 | ||
| Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients | Q37206687 | ||
| Changes to anti-JCV antibody levels in a Swedish national MS cohort | Q37267644 | ||
| First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks | Q37588251 | ||
| Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
| Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab | Q37982013 | ||
| JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab | Q39012188 | ||
| Anti-JC virus antibody titres increase over time with natalizumab treatment. | Q40451346 | ||
| MRI pattern in asymptomatic natalizumab-associated PML. | Q41745436 | ||
| Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy | Q41858218 | ||
| Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy | Q42170814 | ||
| Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial | Q42214743 | ||
| Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? | Q42226607 | ||
| Progressive multifocal leukoencephalopathy after natalizumab discontinuation | Q42255115 | ||
| JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. | Q42266414 | ||
| JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment | Q42282868 | ||
| Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort | Q42648662 | ||
| Isolated motor control dysfunction related to progressive multifocal leukoencephalopathy during AIDS with normal MRI. | Q43447350 | ||
| Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies | Q44417521 | ||
| Anti-JC virus antibodies: implications for PML risk stratification | Q45373492 | ||
| Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab | Q48266103 | ||
| The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? | Q48401612 | ||
| Progressive multifocal leukoencephalopathy after natalizumab monotherapy | Q48463331 | ||
| Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy | Q48527407 | ||
| MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. | Q48829236 | ||
| Value of MRI as a surrogate marker for PML in natalizumab long-term therapy | Q83363676 | ||
| Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS | Q83386697 | ||
| Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance | Q83389204 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| immunosuppressive drug | Q249619 | ||
| globulins | Q321710 | ||
| blood proteins | Q425056 | ||
| progressive multifocal leukoencephalopathy | Q704930 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 117-25 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
| P1476 | title | Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group | |
| P478 | volume | 87 |
| Q33810097 | "Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patients |
| Q57161711 | A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future |
| Q36484448 | Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis |
| Q40100891 | Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. |
| Q54203347 | Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. |
| Q47868961 | Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting |
| Q52659119 | Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. |
| Q55516242 | Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature. |
| Q38931021 | Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis |
| Q38984981 | Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases |
| Q92554913 | Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study |
| Q26744505 | Current status of biomarker research in neurology |
| Q36073992 | Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab |
| Q39705818 | Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system |
| Q38760860 | Disease-modifying therapies and infectious risks in multiple sclerosis |
| Q30815289 | Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases |
| Q50086043 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat |
| Q91635987 | Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy |
| Q33736193 | High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study |
| Q39247449 | Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis. |
| Q92239438 | Immunological Aspects of Approved MS Therapeutics |
| Q59354824 | Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management |
| Q38944786 | Infectious Complications of Novel Multiple Sclerosis Therapies |
| Q50092008 | MRI and multiple sclerosis-the evolving role of MRI in the diagnosis and management of MS: a clinician's perspective |
| Q36400004 | MRI in the assessment and monitoring of multiple sclerosis: an update on best practice |
| Q64091829 | Monoclonal Antibodies in Multiple Sclerosis: Present and Future |
| Q42363059 | Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy |
| Q36290143 | Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis. |
| Q39211049 | Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. |
| Q49950638 | Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification |
| Q39711019 | Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients |
| Q33754882 | Natalizumab in Multiple Sclerosis: Long-Term Management |
| Q28555138 | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry |
| Q48105057 | Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks |
| Q40666987 | Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus |
| Q42650343 | Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease |
| Q41924854 | Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review |
| Q30245002 | Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. |
| Q90529500 | Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies |
| Q91830971 | Progressive Multifocal Leukoencephalopathy: Current Insights |
| Q89777446 | Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review |
| Q64240236 | Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study |
| Q39325788 | Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases |
| Q36394016 | Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment. |
| Q90003732 | Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report |
| Q39269762 | Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy |
| Q38817473 | Some recent advances in multiple sclerosis |
| Q95728280 | Study on JV Virus in Patients with Colon Cancer Type Adenocarcinoma |
| Q40077487 | Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients |
| Q47548881 | Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica |
| Q26745725 | The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes |
| Q38796218 | The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing |
| Q90288758 | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration |
| Q38815391 | Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs |
| Q38871098 | Unintended Immunological Consequences of Biologic Therapy. |
| Q31114633 | Use of natalizumab in multiple sclerosis: current perspectives |
Search more.